Modulation of aromatase expression in human breast tissue

被引:41
作者
Chen, SU [1 ]
Zhou, DJ [1 ]
Yang, C [1 ]
Okubo, T [1 ]
Kinoshita, Y [1 ]
Yu, B [1 ]
Kao, YC [1 ]
Itoh, T [1 ]
机构
[1] City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA
关键词
aromatase; gene regulation; nuclear receptors; aromatase inhibitors; antiestrogens; environmental chemicals;
D O I
10.1016/S0960-0760(01)00132-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Aromatase plays an important role in breast cancer development through its role in the synthesis of estrogen. Aromatase expression in breast tissue can be regulated by several mechanisms. The major promoter usage for aromatase expression in breast tumors (i.e, cAMP-stimulated promoters 1.3 and II) is different from that in normal breast tissue (i.e. glucocorticoid-stimulated promoter 1.4). Recent characterization of transcription factors that interact with the two important regulatory elements near promoters 1.3 and 11, i.e. SI and CREaro, helps us better understand the mechanism of the switch of promoter usage between normal breast tissue and cancer tissue. It is thought that in normal breast tissue, the function of promoters 1.3 and 11 is suppressed through the binding of EAR-2, COUP-TFI, and EARgamma to S1, and through the binding of Snail/Slug proteins to their binding site that quenchs the CREaro activity. In cancer tissue. the expression levels of EAR-2, COUP-TFI, EARgamma, Snail, and Slug decrease, and aromatase expression is then up regulated through the binding of ERRalpha-1 to S1 and the binding of CREB or related factors to CREaro. Results from this and other laboratories reveal that aromatase activity in aromatase expressing cells can also be modified by treatment with aromatase inhibitors and the antiestrogen ICI 182, 780. While aromatase inhibitors are used to treat breast cancer, the treatment has been found to increase the level of aromatase in the breast tissue of some patients. The enhancement of aromatase activity by aromatase inhibitors is thought to be due to a decrease of aromatase protein degradation by enzyme-inhibitor complex formation, up-regulation of the aromatase gene transcription through a cAMP-mediated mechanism, and an induction of aromatase expression by gonadtropins that axe released from the pituitary in response to a reduction of estrogen levels in circulation in premenopausal women. Antiestrogen ICI 182, 780 has been found to suppress aromatase expression, but the mechanism has not yet been determined. In addition, aromatase activity and expression can be affected by environmental chemicals. A detailed structure-function study has revealed that flavones, but not isoflavones, are inhibitors of aromatase. It was found that flavones bind to the active site of aromatase in an orientation in which their rings-A and -C mimic rings-D and -C of the androgen substrate. The modulation of aromatase expression by endocrine disrupting chemicals is exemplified by two organochlorine pesticides (i.e. toxaphene and chlordane) that have been found to be antagonists of ERRalpha-1 orphan receptor. These compounds reduce ERRalpha-1 activity, resulting in a suppression of aromatase expression. (C) 2002 Published by Elsevier Science Ltd.
引用
收藏
页码:35 / 40
页数:6
相关论文
共 23 条
[1]  
Bulun SE, 1997, J STEROID BIOCHEM, V61, P133
[2]   Breast tumor aromatase: functional role and transcriptional regulation [J].
Chen, S ;
Zhou, D ;
Okubo, T ;
Kao, YC ;
Yang, C .
ENDOCRINE-RELATED CANCER, 1999, 6 (02) :149-156
[3]  
Chen SA, 1998, FRONT BIOSCI-LANDMRK, V3, P922
[4]   Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxy-phenyl)-retinamide [J].
Ciolino, HP ;
Wang, TTY ;
Sathyamoorthy, N .
BRITISH JOURNAL OF CANCER, 2000, 83 (03) :333-337
[5]   SHORT-RANGE REPRESSION PERMITS MULTIPLE ENHANCERS TO FUNCTION AUTONOMOUSLY WITHIN A COMPLEX PROMOTER [J].
GRAY, S ;
SZYMANSKI, P ;
LEVINE, M .
GENES & DEVELOPMENT, 1994, 8 (15) :1829-1838
[6]  
Harada N, 1997, J STEROID BIOCHEM, V61, P175
[7]   Inhibitors of aromatase prevent degradation of the enzyme in cultured human tumour cells [J].
Harada, N ;
Hatano, O .
BRITISH JOURNAL OF CANCER, 1998, 77 (04) :567-572
[8]   Aromatase inhibitors and enzyme stability [J].
Harada, N ;
Honda, SI ;
Hatano, O .
ENDOCRINE-RELATED CANCER, 1999, 6 (02) :211-218
[9]   Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: A site-directed mutagenesis study [J].
Kao, YC ;
Zhou, CB ;
Sherman, M ;
Laughton, CA ;
Chen, S .
ENVIRONMENTAL HEALTH PERSPECTIVES, 1998, 106 (02) :85-92
[10]  
Kao YC, 1999, ANTICANCER RES, V19, P2049